Testing a drug to reduce hidden HIV early after treatment start
Treatments studied
Part of Infections clinical trials.
This trial tests whether adding venetoclax, a drug that helps infected cells die, at the start of HIV treatment can lower the amount of hidden virus that stays in the body. It may help reduce the HIV reservoir.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV and have never taken HIV medication before.
- You are between 18 and 70 years old.
- Your CD4 count is above 300 at screening.
- You agree to use condoms during sex until the virus is fully suppressed.
- You are not pregnant, breastfeeding, or planning to get pregnant or father a child during the study.
- You have not taken certain medications that could interact with the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This early-stage trial tests whether two drugs work together to reduce hidden HIV in your body while you're on stable HIV treatment. The goal is to understand how safe the combination is and whether it helps clear dormant HIV cells.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
This trial tests whether adding a new long-acting drug, lenacapavir, to your current HIV treatment can reduce the hidden HIV that remains in your body even when standard treatment keeps the virus undetectable. The goal is to see if this can lead to better control of HIV over time.
This Phase 2 study tests whether UB-421 combined with chidamide can shrink or control the “HIV reservoir,” the hidden HIV in the body that standard treatment may not fully eliminate. It’s mainly for people already on stable HIV medicines with very well-controlled viral levels.
Hear when a new HIV-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.